Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.

Sinisalo M, Silvennoinen R, Wirta O.

Am J Hematol. 2012 Jun;87(6):640. doi: 10.1002/ajh.23189. Epub 2012 Mar 31.

PMID:
22473521
[PubMed - indexed for MEDLINE]
2.

Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.

Ward F, Dunne O, Crotty TB, Fennelly D, Watson A, Holian J.

Ir Med J. 2012 May;105(5):148-9.

PMID:
22803494
[PubMed - indexed for MEDLINE]
3.

[Improved prognosis in light chain nephropathy due to multiple myeloma].

Juul JS, Larsen T, Marcussen N, Pedersen EB.

Ugeskr Laeger. 2012 Apr 23;174(17):1159-60. Danish.

PMID:
22533933
[PubMed - indexed for MEDLINE]
4.

Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.

Hasegawa M, Kondo F, Yamamoto K, Murakami K, Tomita M, Nabeshima K, Nakai S, Kato M, Ohashi A, Arai J, Hiki Y, Ishii J, Emi N, Sugiyama S, Yuzawa Y.

Ther Apher Dial. 2010 Oct;14(5):451-6. doi: 10.1111/j.1744-9987.2010.00863.x.

PMID:
21175542
[PubMed - indexed for MEDLINE]
5.

Renal improvement in myeloma with bortezomib plus plasma exchange.

Burnette BL, Leung N, Rajkumar SV.

N Engl J Med. 2011 Jun 16;364(24):2365-6. doi: 10.1056/NEJMc1101834. No abstract available.

PMID:
21675906
[PubMed - indexed for MEDLINE]
Free Article
6.

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.

Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring HU, Weisel KC.

Ann Hematol. 2012 May;91(5):729-35. doi: 10.1007/s00277-011-1383-0. Epub 2011 Dec 15.

PMID:
22170517
[PubMed - indexed for MEDLINE]
7.

Renal improvement in myeloma with plasma exchange.

Hutchison C, Bridoux F, Fermand JP.

N Engl J Med. 2011 Sep 15;365(11):1061; author reply 1062. doi: 10.1056/NEJMc1108282#SA1. No abstract available.

PMID:
21916654
[PubMed - indexed for MEDLINE]
8.

The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.

Cockwell P, Cook M.

Adv Chronic Kidney Dis. 2012 Sep;19(5):324-32. doi: 10.1053/j.ackd.2012.06.003. Review.

PMID:
22920643
[PubMed - indexed for MEDLINE]
9.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
[PubMed - indexed for MEDLINE]
10.

Renal improvement in myeloma with plasma exchange.

Haspel RL, Cserti-Gazdewich C, Dzik WH.

N Engl J Med. 2011 Sep 15;365(11):1061-2; author reply 1062. doi: 10.1056/NEJMc1108282#SA2. No abstract available.

PMID:
21916653
[PubMed - indexed for MEDLINE]
11.

[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].

de Alarcón Jiménez RM, Roca Meroño S, Alvarez Fernández GM, García Hernández MA, Navarro Parreño MJ, Jimeno Griñó C, Zarco Pedrinaci E, Molina Núñez M.

Nefrologia. 2011;31(2):238-40. doi: 10.3265/Nefrologia.pre2010.Aug.10496. Review. Spanish. No abstract available.

PMID:
21461027
[PubMed - indexed for MEDLINE]
Free Article
12.

Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D.

Nephrol Dial Transplant. 2012 Oct;27(10):3823-8. doi: 10.1093/ndt/gfr773. Epub 2012 Jan 23.

PMID:
22273664
[PubMed - indexed for MEDLINE]
13.

Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.

Borrego-Hinojosa J, Pérez-del Barrio MP, Biechy-Baldan Mdel M, Merino-García E, Sánchez-Perales MC, García-Cortés MJ, Ocaña-Pérez E, Gutiérrez-Rivas P, Liébana-Cañada A.

Nefrologia. 2013;33(4):515-23. doi: 10.3265/Nefrologia.pre2013.Feb.11932. English, Spanish.

PMID:
23897183
[PubMed - indexed for MEDLINE]
Free Article
14.

Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.

Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.

Transplant Proc. 2009 Dec;41(10):4407-10. doi: 10.1016/j.transproceed.2009.10.005.

PMID:
20005409
[PubMed - indexed for MEDLINE]
15.

Lenalidomide efficacy in bortezomib-resistant myeloma.

Gozzetti A, Crupi R, Defina M, Bocchia M.

Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c2; author reply doi:10.1038/nrclinonc.2010.31-c3. No abstract available.

PMID:
20824907
[PubMed - indexed for MEDLINE]
16.

[New insights in the treatment of myeloma with renal failure].

Moumas E, Hanf W, Desport E, Abraham J, Delbès S, Debiais C, Lacotte-Thierry L, Touchard G, Jaccard A, Fermand JP, Bridoux F.

Nephrol Ther. 2011 Nov;7(6):457-66. doi: 10.1016/j.nephro.2011.03.002. Epub 2011 Apr 23. Review. French.

PMID:
21515102
[PubMed - indexed for MEDLINE]
17.

Management options for cast nephropathy in multiple myeloma.

Cockwell P, Hutchison CA.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):550-5. doi: 10.1097/MNH.0b013e32833ef72c. Review.

PMID:
20827195
[PubMed - indexed for MEDLINE]
18.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
[PubMed - indexed for MEDLINE]
19.

Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.

Qayum A, Aleem A, Al Diab AR, Niaz F, Al Momen AK.

Saudi J Kidney Dis Transpl. 2010 Jan;21(1):63-8.

PMID:
20061695
[PubMed - indexed for MEDLINE]
Free Article
20.

Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.

Kumar V, Elkins S, Gaston RS, Prendergast MB, Reddy V, Cook WJ, Sanders PW.

Clin Transpl. 2009:439-41.

PMID:
20524312
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk